INSPInspire Medical Systems, Inc.

Healthcare

$71.06-8.1% 1Y

$71.06

$40.0552 weeks$143.99

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in, but rich vs its sector.

1 good, 1 to watch, 1 without data

What the price assumes~+4% a year

Priced for ~4% a year FCF growth. The price demands less than its three-year revenue growth of 20% a year, expectations look modest.

Vs sector (EV/EBIT)32.3×

Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

All from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)better than 70% of the market

FCF yieldmiddle of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What INSP's price assumes

Inspire Medical Systems, Inc. trades at 15.7× earnings against 28.1× for the median Medical Devices name, cheaper than its own group.

15.7

Trailing P/E · Medical Devices median 28.1 · cheaper than the typical name in its group

Price / sales: 2.29
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 5.7%
Free cash flow yield · Medical Devices median 4.0%
Growth the price implies: +3.9%
Growth the price implies · The price pays for +3.9% free cash flow growth a year for a decade; the business has delivered +84% a year over the last three.